iRadimed Corporation (IRMD) valuation against sector peers: P/E 46.6 (sector median 30.6), P/B 10.5, EV/EBIT 36.8, free-cash-flow yield 2.3%, P/S 12.4.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Metric	IRMD	Sector median	vs median
P/E	46.6	30.6 · n=152	52% above
P/B	10.5	4.0 · n=305	163% above
P/S	12.4	4.4 · n=297	180% above
EV/EBIT	36.8	25.8 · n=139	43% above
Free-cash-flow yield	2.3%	1.4% · n=287	65% above
Dividend yield	0.92%	0.00% · n=358	—
Return on equity	23.5%	−3.7% · n=306	—
Return on invested capital	50.9%	0.4% · n=275	11,559% above
Gross margin	75.9%	61.7% · n=202	23% above
Net debt / EBITDA	−2.02	1.31 · n=146	254% below

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Value factor: 52 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

Instrument	P/E	P/B	EV/EBIT	Free-cash-flow yield	Dividend yield	Smart Score
LLYEli Lilly & Co	45.4	35.8	—	1.5%	0.6%	7/10
JNJJohnson & Johnson	40.5	8.0	—	3.2%	1.9%	8/10
ABBVAbbVie	80.6	—	33.8	3.6%	3.0%	5/10
UNHUnitedHealth	25.9	3.5	19.1	6.5%	2.2%	9/10
MRKMerck	109.6	8.3	—	4.6%	2.4%	9/10
TMOThermo Fisher Scientific	37.4	4.9	36.7	2.8%	0.3%	10/10
AMGNAmgen	27.9	20.9	25.2	4.2%	2.2%	7/10
GILDGILEAD	—	16.7	—	6.6%	2.0%	5/10
ABTAbbott	28.4	3.4	26.8	4.1%	3.0%	6/10
PFEPfizer	38.7	2.0	—	6.5%	7.3%	1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Jun 2026 · filed 31 Jul 2026

Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.

Cookie settings